CytomX Therapeutics CTMX
NASDAQ CTMX
$2.56 -0.07 (-2.66%)
At close: Oct 2, 2026 · 4:00 PM EDT

CytomX Therapeutics (CTMX) Return on Sales [ROS] (2014 - 2026)

Updated

CytomX Therapeutics (CTMX) posted Return on Sales [ROS] of -1677.08% for Q2 2026, down 1670.19 percentage points from -6.89% a year earlier and down 1485.31 percentage points from the prior quarter.

Analysis

CytomX Therapeutics (CTMX) Return on Sales [ROS] (2014 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at CytomX Therapeutics was -476.19%, down 506.76 percentage points year-over-year; for FY2025, it came in at -29.35%, down 47.45 percentage points from FY2024.

  • Annual Return on Sales [ROS] shows a five-year change of +88.35 percentage points (FY2020 to FY2025).
  • In prior years, CytomX Therapeutics' Return on Sales [ROS] was 18.10% in FY2024 (+24.51 pp), -6.41% in FY2023 (+184.21 pp), -190.61% in FY2022 (+120.39 pp) and -311.00% in FY2021 (-193.30 pp).
  • Quarterly Return on Sales [ROS] has run from a low of -4212.97% in Q4 2025 to a high of 46.41% in Q4 2024 over five years.
  • On a year-over-year basis, Return on Sales [ROS] has declined in each of the last four quarters, with an average year-over-year change of -793.78 percentage points over the last eight quarters.
  • The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was Q1 2023, with a gain of 330.61 percentage points; the weakest was Q4 2025, with a drop of 4259.38 percentage points.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -191.77% (Q1 2026), -4212.97% (Q4 2025) and -264.43% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 28.21%
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 37.86%
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 32.97%
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 20.57%
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 34.95%
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -133.21%
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 28.37%
10 CytomX Therapeutics 573.08 Mn -384.59 Mn - -1,677.08%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1,677.08%
Mar 31, 2026 -191.77%
Dec 31, 2025 -4,212.97%
Sep 30, 2025 -264.43%
Jun 30, 2025 -6.89%
Mar 31, 2025 44.43%
Dec 31, 2024 46.41%
Sep 30, 2024 12.30%
Jun 30, 2024 -33.65%
Mar 31, 2024 28.11%
Dec 31, 2023 -2.28%
Sep 30, 2023 11.84%
Jun 30, 2023 -13.54%
Mar 31, 2023 -24.06%
Dec 31, 2022 -47.25%
Sep 30, 2022 -266.53%
Jun 30, 2022 -233.83%
Mar 31, 2022 -354.67%
Dec 31, 2021 -313.54%
Sep 30, 2021 -337.78%
API Access

CytomX Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CTMX&period=max&api_key=YOUR_API_KEY